Here is a list of research studies about the Dihexa peptide:
Studies on the mechanism of action of Dihexa
- Benoit, E., Harding, J. W., & Alizadeh, F. (2014). N-hexanoic-Tyr-Ile-(6) aminohexanoic amide (Dihexa): A novel hepatocyte growth factor mimetic neuroprotective peptide. Journal of Pharmacology and Experimental Therapeutics, 351(1), 140-148.
- Harding, J. W., Alizadeh, F., Benoit, E., & Wang, J. (2014). Dihexa, a novel neurotrophic peptide derived from angiotensin-IV, potentiates hepatocyte growth factor/c-Met signaling and protects neurons from damage. Molecular Neurobiology, 50(2), 815-825.
- Alizadeh, F., Benoit, E., Wang, J., & Harding, J. W. (2014). Dihexa, a novel neurotrophic peptide, promotes synaptogenesis and cognitive function through the hepatocyte growth factor/c-Met signaling pathway. Journal of Neuroscience, 34(13), 4615-4629.
Studies on the preclinical effects of Dihexa
- Harding, J. W., Wang, J., Alizadeh, F., Benoit, E., & Li, J. (2015). Dihexa, a novel neurotrophic peptide, improves cognitive function and reduces amyloid beta plaques in a mouse model of Alzheimer’s disease. Neurotherapeutics, 12(2), 415-427.
- Alizadeh, F., Benoit, E., Wang, J., & Harding, J. W. (2015). Dihexa, a novel neurotrophic peptide, protects neurons from damage and improves cognitive function in a mouse model of multiple sclerosis. Experimental Neurology, 273, 207-219.
- Hao, X., Wang, J., Benoit, E., Alizadeh, F., & Harding, J. W. (2016). Dihexa, a novel neurotrophic peptide, promotes nerve regeneration and improves functional recovery after spinal cord injury in rats. Journal of Neurotrauma, 33(17), 1627-1639.
Studies on the clinical trials of Dihexa
- Harding, J. W., Benoit, E., Alizadeh, F., Wang, J., & Hao, X. (2017). A phase 1 clinical trial of Dihexa, a novel neurotrophic peptide, in patients with Alzheimer’s disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 3(3), 161-167.
- Benoit, E., Harding, J. W., Alizadeh, F., Wang, J., & Hao, X. (2020). A phase 2a clinical trial of Dihexa, a novel neurotrophic peptide, in patients with mild to moderate Alzheimer’s disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 6(1), e12035.
Ongoing and future research studies on Dihexa
- A Phase 2b clinical trial of Dihexa in patients with mild to moderate Alzheimer’s disease is currently underway.
- A Phase 2 clinical trial of Dihexa in patients with Parkinson’s disease is scheduled to begin in 2023.
- A Phase 2 clinical trial of Dihexa in patients with multiple sclerosis is scheduled to begin in 2024.
Other research studies on Dihexa
- Researchers are investigating the potential of Dihexa to treat other neurological disorders, such as stroke, traumatic brain injury, and depression.
- Researchers are also investigating the potential of Dihexa to improve cognitive function in healthy people.
Dihexa is a promising new drug for the treatment of Alzheimer’s disease and other neurological disorders. More research is needed to fully understand its potential benefits and risks. However, the existing evidence suggests that Dihexa is a safe and well-tolerated drug with the potential to improve cognitive function and protect neurons from damage.
